FLNA Earnings — Filana Therapeutics, Inc. Common Stock Post-ER Performance | BigEarnings
FLNA — Filana Therapeutics, Inc. Common Stock
XNAS
Price$0.92
Market Cap$44.4M
P/E—
52W Range$0.85 – $2.27
Next Earnings2026-11-11
About Filana Therapeutics, Inc. Common Stock
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.